Regulatory role of CD39 and CD73 in tumor immunity

被引：6
|
作者：
Kaplinsky, Nicole [1 ]
Williams, Kada [1 ]
Watkins, Dean [1 ]
Adams, Molly [1 ]
Stanbery, Laura [2 ]
Nemunaitis, John [2 ]
机构：
[1] Univ Toledo, Coll Med, Toledo, OH 43614 USA
[2] Gradalis Inc, Dallas, TX 75006 USA
来源：
FUTURE ONCOLOGY | 2024年 / 20卷 / 19期
关键词：
adenosine pathway; antigen; CD39; CD73; ENTPD1; immunotherapy; tumor microenvironment; T-CELLS; EXTRACELLULAR ADENOSINE; ATP; DISEASE; GROWTH; CANCER; INHIBITION; THERAPY;
D O I：
10.2217/fon-2023-0871
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP). In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.
引用
收藏
页码：1367 / 1380
页数：14
相关论文
共 50 条
  • [31] CD73 promotes tumor growth and metastasis
    Zhang, Bin
    ONCOIMMUNOLOGY, 2012, 1 (01): : 67 - 70
  • [32] Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
    Yang, Jiayin
    Liao, Xiaohong
    Yu, Jerry
    Zhou, Ping
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (19) : 2260 - 2271
  • [33] Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation
    Festag, Julia
    Thelemann, Tamara
    Schell, Monika
    Raith, Stefanie
    Michel, Sven
    Jaschinski, Frank
    Klar, Richard
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 21 : 656 - 669
  • [34] Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells
    Schuler, P. J.
    Saze, Z.
    Hong, C. -S.
    Muller, L.
    Gillespie, D. G.
    Cheng, D.
    Harasymczuk, M.
    Mandapathil, M.
    Lang, S.
    Jackson, E. K.
    Whiteside, T. L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 177 (02) : 531 - 543
  • [35] Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
    Perrot, Ivan
    Michaud, Henri-Alexandre
    Giraudon-Paoli, Marc
    Augier, Severine
    Docquier, Aurelie
    Gros, Laurent
    Courtois, Rachel
    Dejou, Cecile
    Jecko, Diana
    Becquart, Ondine
    Rispaud-Blanc, Helene
    Gauthier, Laurent
    Rossi, Benjamin
    Chanteux, Stephanie
    Gourdin, Nicolas
    Amigues, Beatrice
    Roussel, Alain
    Bensussan, Armand
    Eliaou, Jean-Francois
    Bastid, Jeremy
    Romagne, Francois
    Morel, Yannis
    Narni-Mancinelli, Emilie
    Vivier, Eric
    Paturel, Carine
    Bonnefoy, Nathalie
    CELL REPORTS, 2019, 27 (08): : 2411 - +
  • [36] A short review of CD73 Role in Cancer
    Akbari, Farhad Hariri
    Slemc, Lucija
    Alizadeh, Mahdi
    Fard, Mahnaz Hatami
    Shafaei, Peymaneh
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (07): : 211 - 219
  • [37] Targeting CD73 in the tumor microenvironment with MEDI9447
    Hay, Carl M.
    Sult, Erin
    Huang, Qihui
    Mulgrew, Kathy
    Fuhrmann, Stacy R.
    McGlinchey, Kelly A.
    Hammond, Scott A.
    Rothstein, Raymond
    Rios-Doria, Jonathan
    Poon, Edmund
    Holoweckyj, Nick
    Durham, Nicholas M.
    Leow, Ching Ching
    Diedrich, Gundo
    Damschroder, Melissa
    Herbst, Ronald
    Hollingsworth, Robert E.
    Sachsenmeier, Kris F.
    ONCOIMMUNOLOGY, 2016, 5 (08):
  • [38] Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
    Li, Xian-Yang
    Moesta, Achim K.
    Xiao, Christos
    Nakamura, Kyohei
    Casey, Mika
    Zhang, Haiyan
    Madore, Jason
    Lepletier, Ailin
    Aguilera, Amelia Roman
    Sundarrajan, Ashmitha
    Jacoberger-Foissac, Celia
    Wong, Clifford
    dela Cruz, Tracy
    Welch, Megan
    Lerner, Alana G.
    Spatola, Bradley N.
    Soros, Vanessa B.
    Corbin, John
    Anderson, Ana C.
    Effern, Maike
    Hoelzel, Michael
    Robson, Simon C.
    Johnston, Rebecca L.
    Waddell, Nicola
    Smith, Corey
    Bald, Tobias
    Geetha, Nishamol
    Beers, Courtney
    Teng, Michele W. L.
    Smyth, Mark J.
    CANCER DISCOVERY, 2019, 9 (12) : 1754 - 1773
  • [39] Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
    Kolbe, Clara
    Kauer, Joseph
    Brinkmann, Berit
    Dreger, Peter
    Huber, Wolfgang
    Mueller-Tidow, Carsten
    Dietrich, Sascha
    Roider, Tobias
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [40] IMMUNOHISTOCHEMICAL AND FUNCTIONAL ANALYSIS OF ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1 (CD39) AND ECTO-5′-NUCLEOTIDASE (CD73) IN PIG AORTIC VALVES
    Kaniewska, Ewa
    Sielicka, Alicja
    Sarathchandra, Padmini
    Pelikant-Malecka, Iwona
    Olkowicz, Mariola
    Slominska, Ewa M.
    Chester, Adrian H.
    Yacoub, Magdi H.
    Smolenski, Ryszad T.
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2014, 33 (4-6) : 305 - 312
12345